Find a Clinical Trial
With our more than 160 cancer researchers and physicians working together, we’re making scientific discoveries that translate into better treatments and better health for our patients. In fact, some of our treatments are used in hospitals around the country and the world.
If you’re a current patient, the first step is to talk to your doctor about trials that you might be eligible for. Keep in mind that we open new trials often, so check the clinical trials directory below for a complete list of active studies.
If you and your doctor decide a clinical trial is best, a UAMS research team that includes doctors, nurses, social workers, dietitians, and other health care professionals will work with you. They will provide your care, monitor your health carefully, and give you specific instructions about the study.
Clinical Trial Questions?
Call 501-686-8288 or email CancerClinicalTrials@uams.edu
IRB #276276 – A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
PI: Dr. Schinke – Sponsor: Janssen
The purpose of this research study is to help researchers understand more about the potential benefits and safety of 2 study drugs, talquetamab (also known as JNJ-64407564) and teclistamab (also known as JNJ-64007957), when given in combination to participants with a type of multiple myeloma (MM) “Extramedullary Disease (EMD)” that has gotten worse after other standard or approved treatment. EMD is tumor growth outside of the bone or bone marrow. The combination of teclistamab and talquetamab are experimental and has not been approved by the US Food and Drug Administration for treatment of your illness. Learn More
IRB #229129 – EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
PI: Dr. Bryant-Smith – Sponsor: ECOG
This study is being done to answer the following question:
Can tomosynthesis mammography, three-dimensional x-ray imaging of the breast, lower your chance of developing life-threatening breast cancer through routine screening compared with digital mammography, two-dimensional x-ray imaging of the breast?
We are doing this study because we want to find out which of the two usual approaches to breast cancer screening are better in the early detection of life-threatening breast cancers. Learn More
IRB #276489 – A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
PI: Dr. Birrer – Sponsor: Exelixis
The purpose of this study is to find the highest dose of the study drug XB002, when given alone and in combination with nivolumab or bevacizumab , without causing too many side effects. We will measure how your body and your cancer react to the study drug(s). We want to find out what effects, good or bad, the study drug(s) have on you and your cancer and if they are effective in treating your type of cancer. XB002 is an intravenous (IV, given through a vein) anti-cancer drug. XB002 is considered an experimental drug for use in this study because it has not been approved by the Food and Drug Administration (FDA) and this is the first time this drug has been tested in people. Learn More